ORYZON Presents Data for Iadademstat Combinations in AML at the American Society of Hematology (ASH) 67th Annual Meeting

Core Insights - Oryzon Genomics reported promising clinical data for iadademstat, a selective LSD1 inhibitor, in treating acute myeloid leukemia (AML) at the 67th ASH Annual Meeting, indicating potential for significant clinical benefits in combination with standard therapies [1][4] Group 1: Clinical Study Results - The ALICE-2 study showed a 100% overall response rate (ORR) and a 90% composite complete remission (CCR) rate in newly diagnosed AML patients treated with iadademstat, azacitidine, and venetoclax [2][5] - In the FRIDA study, 67% CCR and 47% combined CR and CRh were observed in patients with FLT3-mutant relapsed/refractory AML, demonstrating the efficacy of iadademstat combined with gilteritinib [3][5] Group 2: Safety and Tolerability - Both clinical studies reported that iadademstat was safe and well tolerated, with adverse event profiles comparable to other combination treatments in AML [2][3] - The ongoing dose-finding studies are focused on determining the maximum tolerated dose (MTD) for iadademstat in these patient populations [2][3] Group 3: Future Development and Strategic Partnerships - The CEO of Oryzon emphasized the potential of iadademstat as a best-in-class combination agent, indicating plans for future clinical development and exploration of strategic partnerships to maximize its value [4][6] - Oryzon is also expanding iadademstat's clinical applications beyond hematological cancers, with ongoing trials in sickle cell disease and essential thrombocythemia [7]